Skip to main content
. 2012 Oct 10;13(10):12925–12938. doi: 10.3390/ijms131012925

Figure 2.

Figure 2

Anatomic site-related differences in HAS and HYAL mRNA expression. Graphic illustration of the differences in HAS1-3 and HYAL2 mRNA expression between ovarian carcinoma effusions, primary ovarian carcinomas and solid metastases. HAS1 mRNA expression is significantly higher expression in effusions compared to the two other anatomic sites (p < 0.001); HAS2 mRNA levels are higher in solid metastases and primary carcinomas compared to effusions (p = 0.043); HAS3 mRNA expression levels are significantly higher in primary carcinomas and effusions compared to solid metastases (p = 0.008); HYAL2-var1 expression is comparable in effusions, primary carcinomas and solid metastases (p = 0.44); HYAL2-var2 expression is significantly higher in solid metastases compared to effusions and primary carcinomas (p < 0.001); HYAL3-WT expression is higher in primary carcinomas and effusions compared to solid metastases, though not significantly (p = 0.094). HYAL3-var1-3 expression is significantly higher in primary carcinomas and effusions compared to solid metastases (p = 0.006). The bars on the Y-axis represent arbitrary units.